Guggenheim initiated coverage on Tourmaline with a new price target
$TRML
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Guggenheim initiated coverage of Tourmaline with a rating of Buy and set a new price target of $50.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/6/2025 | $42.00 | Outperform | Wedbush |
| 12/6/2024 | $50.00 | Outperform | BMO Capital Markets |
| 11/11/2024 | $48.00 → $49.00 | Buy | H.C. Wainwright |
| 12/15/2023 | $41.00 | Buy | Jefferies |
| 12/4/2023 | $48.00 | Buy | H.C. Wainwright |
| 11/17/2023 | $43.00 | Buy | Truist |
| 10/31/2023 | $50.00 | Buy | Guggenheim |
| 10/25/2023 | $65.00 | Overweight | Piper Sandler |
NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Paul M. Ridker, MD, MPH, Eugene Braunwald Professor of Medicine at the Harvard Medical School and Director of the Center for Cardiovascular Disease Prevention at Brigham and Women's Hospital, has joined Tourmaline's Cardiovascular Scientific Advisory Board (CV SAB). "We are beyond honored to welcome Dr. Ridker, a luminary in the field who has helped to fundamentally transform our understanding of card
Appointments include industry veterans Aaron Kantoff, Jonathan Goldman, and Samantha Truex as Independent DirectorsBoard of Director appointments in conjunction with Avalo's recent acquisition of AVTX-009, an anti-IL-1β mAb, and up to $185 million private placement financing WAYNE, Pa. and ROCKVILLE, Md., April 02, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX) today announced the addition of multiple biotech leaders to its Board of Directors. The Avalo Board brings together a team with expertise spanning finance, business operations, drug discovery and clinical development. "I am honored to announce these additions to our Board of Directors and welcome their operationa
NEW YORK, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. ("Tourmaline") (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, announced today that Clay Siegall, PhD, has been appointed as Chairman of the Board. "We are absolutely thrilled that Clay has joined Tourmaline as Chairman of the Board," said Sandeep Kulkarni, MD, Co-Founder and Chief Executive Officer of Tourmaline. "Clay built Seagen into one of the largest independent biotech companies in the world by taking a therapeutic concept and developing from it multiple successful medicines
S-8 - Tourmaline Bio, Inc. (0001827506) (Filer)
10-K - Tourmaline Bio, Inc. (0001827506) (Filer)
8-K - Tourmaline Bio, Inc. (0001827506) (Filer)
Wedbush initiated coverage of Tourmaline with a rating of Outperform and set a new price target of $42.00
BMO Capital Markets initiated coverage of Tourmaline with a rating of Outperform and set a new price target of $50.00
H.C. Wainwright reiterated coverage of Tourmaline with a rating of Buy and set a new price target of $49.00 from $48.00 previously
– Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease over-enrolled to 143 total participants, on track to report topline data in the second quarter of 2025 – – Cardiovascular Scientific Advisory Board strengthened with recent appointments of Drs. Deepak L. Bhatt, Dipender Gill, Paul M. Ridker, and Tabassome Simon – – Cash, cash equivalents, and investments of $294.9 million as of December 31, 2024, providing expected cash runway into the second half of 2027 – NEW YORK, March 13, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ:TRML), a late-stage clinical biotechnology company developing transf
NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep Kulkarni, MD, Co-Founder and Chief Executive Officer, is expected to participate in the following investor conference: Leerink's Global Healthcare Conference 2025, MiamiFireside ChatTuesday, March 11, 2025, at 4:20 pm ET A live webcast and replay, when available, will be available under "Events and Presentations" in the News & Investors section of the Tourmaline Bio website at ir.tourmalineb
NEW YORK, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep Kulkarni, MD, Co-Founder and Chief Executive Officer, is expected to participate in the following investor conference: Guggenheim Securities SMID Cap Biotech Conference, New YorkFireside ChatWednesday, February 5, 2025, at 1:30 pm ET A live webcast and replay, when available, will be available under "Events and Presentations" in the News & Investors section of the Tourmaline Bio website at i
SC 13G/A - Tourmaline Bio, Inc. (0001827506) (Subject)
SC 13G/A - Tourmaline Bio, Inc. (0001827506) (Subject)
SC 13G/A - Tourmaline Bio, Inc. (0001827506) (Subject)
4 - Tourmaline Bio, Inc. (0001827506) (Issuer)
4 - Tourmaline Bio, Inc. (0001827506) (Issuer)
4 - Tourmaline Bio, Inc. (0001827506) (Issuer)
4 - Tourmaline Bio, Inc. (0001827506) (Issuer)
4 - Tourmaline Bio, Inc. (0001827506) (Issuer)